Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
56.15
+2.24 (4.16%)
At close: Feb 6, 2026, 4:00 PM EST
55.92
-0.23 (-0.41%)
After-hours: Feb 6, 2026, 7:43 PM EST
Vaxcyte Employees
Vaxcyte had 414 employees as of December 31, 2024. The number of employees increased by 160 or 62.99% compared to the previous year.
Employees
414
Change (1Y)
160
Growth (1Y)
62.99%
Revenue / Employee
n/a
Profits / Employee
-$1,587,442
Market Cap
8.06B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 414 | 160 | 62.99% |
| Dec 31, 2023 | 254 | 96 | 60.76% |
| Dec 31, 2022 | 158 | 69 | 77.53% |
| Dec 31, 2021 | 89 | 31 | 53.45% |
| Dec 31, 2020 | 58 | 15 | 34.88% |
| Dec 31, 2019 | 43 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Jazz Pharmaceuticals | 2,800 |
| Axsome Therapeutics | 816 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 498 |
| Halozyme Therapeutics | 350 |
| Rhythm Pharmaceuticals | 283 |
| Krystal Biotech | 275 |
| Nuvalent | 218 |
PCVX News
- 3 days ago - Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit - GlobeNewsWire
- 6 days ago - Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 10 days ago - Vaxcyte Announces Pricing of $550 Million Public Offering - GlobeNewsWire
- 10 days ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha
- 10 days ago - Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 17 days ago - Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine - GlobeNewsWire
- 6 weeks ago - This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%. - Barrons
- 7 weeks ago - Vaxcyte: Financial Durability And The Case For Disruption - Seeking Alpha